Dicot Pharma Dicot Pharma
På svenska

Warrant exercise results finalized!

With a 96% subscription rate generating SEK 43.8 million, we are now able to continue executing our ambitious development plan.

Watch the video from our Nasdaq First North listing

Phase 2a clinical study in full swing.

On our journey towards offering the market the next generation erectile dysfunction treatments, we have now entered Phase 2 clinical trials.

  • Home/
  • Investor Relations

Investor Relations

Dicot Pharma aims to launch the drug candidate LIB-01 globally and become the first-choice treatment for erectile dysfunction and premature ejaculation. Our global ambition means we are gradually increasing international efforts in development, business, and communications.

Dicot Pharma currently has over 9,100 shareholders. Since 2024, the stock has been listed on Nasdaq First North Stockholm.

IR Contact

Elin Trampe

CEO

Email: [email protected]
Telephone: +46 72 502 1010